Menu
Search
|

Menu

Close
X

Proteostasis Therapeutics Inc PTI.OQ (NASDAQ Stock Exchange Global Market)

2.93 USD
-- (--)
As of Feb 22
chart
Previous Close 2.93
Open --
Volume --
3m Avg Volume 255,909
Today’s High --
Today’s Low --
52 Week High 15.28
52 Week Low 1.41
Shares Outstanding (mil) 33.11
Market Capitalization (mil) 97.02
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
4
FY16
8
FY15
4
EPS (USD)
FY17
-1.837
FY16
-2.256
FY15
-1.220
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.75
Price to Sales (TTM)
vs sector
12.47
8.23
Price to Book (MRQ)
vs sector
1.92
5.26
Price to Cash Flow (TTM)
vs sector
--
26.16
Total Debt to Equity (MRQ)
vs sector
0.00
15.44
LT Debt to Equity (MRQ)
vs sector
0.00
12.05
Return on Investment (TTM)
vs sector
-78.29
13.63
Return on Equity (TTM)
vs sector
-86.40
15.25

EXECUTIVE LEADERSHIP

M. James Barrett
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Meenu Chhabra
President, Chief Executive Officer, Director, Since 2014
Salary: $450,138.00
Bonus: $232,500.00
Helen Boudreau
Chief Financial Officer, Principal Accounting Officer, Treasurer, Since 2017
Salary: --
Bonus: --
Marija Zecevic
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Po-Shun Lee
Executive Vice President, Chief Medical Officer, Since
Salary: $334,892.00
Bonus: $119,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 Technology Sq
CAMBRIDGE   MA   02139-3578

Phone: +1617.2250096

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.

SPONSORED STORIES